Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Avecho Biotechnology Limited ( (AU:AVE) ) has provided an update.
Avecho Biotechnology has received A$1.98 million under the Australian Government’s R&D Tax Incentive Scheme for the year ended 31 December 2025, underscoring its ongoing investment in differentiated cannabinoid formulations aimed at pharmaceutical registration. The company will use most of the funds to repay A$1.62 million advanced by Endpoint Capital against its tax credit, while the balance will support operations and help progress commercialisation of its CBD TPM soft-gel capsule, a Phase III-stage candidate in a sizeable insomnia and sleep-aids market where Avecho is positioning to be an early over-the-counter CBD entrant in Australia.
The payment strengthens Avecho’s near-term funding for its pivotal, multi-centre Phase III trial in adults with insomnia, a condition that affects a significant portion of the global and Australian populations and has been recognised domestically as a national health priority. Success in this trial could enable a regulatory submission for over-the-counter pharmacy sales of its CBD product in Australia, potentially giving Avecho first-mover advantage in a market that has been projected to reach more than US$125 million annually for OTC CBD products, thereby enhancing its competitive standing and value proposition to investors and partners.
More about Avecho Biotechnology Limited
Avecho Biotechnology Limited is an Australian drug-delivery and biotechnology company developing human and animal health products based on its proprietary Tocopheryl Phosphate Mixture (TPM) platform, derived from vitamin E. Its lead asset is a TPM-enhanced cannabidiol soft-gel capsule designed to improve CBD absorption and is currently in Phase III clinical development for the treatment of insomnia, targeting the large and growing global sleep-disorder market.
Average Trading Volume: 9,836,848
Technical Sentiment Signal: Sell
Current Market Cap: A$45.97M
Learn more about AVE stock on TipRanks’ Stock Analysis page.